Genentech Unveils 5-Year Data for Susvimo: Long-Term Efficacy and Durability in Wet AMD Treatment
Genentech announced new 5-year data from the phase 3 Portal study, which the company says reaffirms the long-term efficacy, safety, and durability of Susvimo (ranibizumab injection) in treating wet age-related macular degeneration (AMD). The findings were presented this week at the American Society of Retina Specialists (ASRS) 2025 annual meeting in Long Beach, CA.
The Portal study, an extension of the phase 3 Archway trial, followed 352 patients previously enrolled in Archway. Results demonstrated that approximately 95% of patients receiving Susvimo every 6 months required no supplemental treatment between refill visits. This sustained performance reduces the treatment burden compared to monthly anti-VEGF intravitreal injections.
“These long-term results reinforce Susvimo’s ability to maintain vision and retinal drying over a long period of time for people with wet AMD, the leading cause of vision loss in people over age 60," said Levi Garraway, MD, PhD, Chief Medical Officer and Head of Global Product Development at Genentech.
Data showed strong visual outcomes across both cohorts:
- Susvimo Cohort:
- BCVA: 74.4 letters at baseline, 67.6 letters at year 5
- CST: 1.4 µm reduction (95% CI: -13.1, 11.1) from baseline
- IVT-Susvimo Cohort:
- BCVA: 76.3 letters at baseline, 68.6 letters at year 5
- CST: 4.2 µm reduction (95% CI: -25.7, 5.0)
Notably, half of all patients maintained 20/40 vision or better at 5 years. These figures reflect consistent disease control and visual preservation for a population that began the study with near-peak visual acuity after prior anti-VEGF treatment.
“This study reinforces that continuous drug delivery via Susvimo may lead to more durable outcomes in real-world scenarios than traditional injection regimens,” said John Kitchens, MD, Retina Associates of Kentucky, who presented the data at ASRS.
Susvimo is administered through the Port Delivery Platform—a refillable intraocular implant surgically inserted during a one-time outpatient procedure. The device allows for continuous intraocular delivery of a specialized ranibizumab formulation over 6-month intervals, offering patients an alternative to frequent injections.
This 5-year dataset from the largest long-term prospective cohort of wet AMD patients supports broader adoption of the device across eligible patient populations.
Archway (NCT03677934) is a randomized, multicenter, open-label phase 3 trial comparing fixed 6-month Susvimo refills with monthly intravitreal ranibizumab injections in 415 patients. Portal is an ongoing extension of Archway following patients for long-term outcomes across both Susvimo-initiated and transitioned cohorts. Participants were responders to prior anti-VEGF therapy and had received at least three (average of five) intravitreal injections before entering Archway.